Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of keverprazan hydrochloride injection to reduce rebleeding after endoscopic hemostasis in peptic ulcer bleeding
CTR20251331Phase 3Completed
- Sponsor
- 江苏柯菲平医药股份有限公司/ 南京柯菲平盛辉制药有限公司
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of keverprazan in Peptic ulcer disease (PUD), upper gastrointestinal bleeding (UGIB), sponsored by 江苏柯菲平医药股份有限公司/ 南京柯菲平盛辉制药有限公司. Started Apr 2025; status: completed.
02
Drugs
keverprazan
03
Conditions
Peptic ulcer disease (PUD)upper gastrointestinal bleeding (UGIB)
Beyond the preview
Go deeper on CTR20251331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251331.